Learn more about Healthcare issues that concern you.
Read Press Statements and Op Eds Published by RetireSafe
Washington, DC (February 8, 2024) – RetireSafe issued the following statement regarding the Senate HELP Committee’s hearing on U.S. drug prices in comparison to foreign countries:
“Our nation’s seniors have access to the most advanced prescription drugs and treatments, thanks to our flourishing medical breakthrough ecosystem. Some lawmakers threaten to disrupt this ecosystem with policies that would empower the federal government to reference foreign countries’ pricing schemes. What they fail to understand is that patients in these countries do not enjoy timely access to advanced, life-saving treatment like we do in America. In fact, their older adults are subject to discriminatory practices that put those with rare diseases and disabilities at the back of the line.
This is largely because those countries impose access restrictions as a side effect of their price control policies that disincentivize medical advancements. Any consideration of mimicking these policies in our Medicare program would be a detriment to our nation’s seniors, disrupting their access to meaningful care and ripping potential treatments right out from under those in need. We urge Congress to reconsider these policies.”
As policymakers consider cuts to seniors' Medicare Advantage benefits, it's important that they hear from seniors on the importance of their coverage and benefits. If you are a senior enrolled in Medicare Advantage, we want to hear from you!
Please take a moment and participate in our survey...
Dear RetireSafe Advocates,
Our friends over at Seniors Speak Out are hosting a Facebook Live on June 15 at 2:00 PM ET, and RetireSafe’s President & CEO Mark Gibbons is pleased to join the senior healthcare advocacy group as a guest at the event. We want to invite you to tune in as Mark and SSO Spokesperson Thair Phillips discuss this year’s healthcare legislative priorities. Seniors’ access to healthcare continues to be a number one issue that advocates like yourselves should be informed of!
During the event, Mark and Thair plan on sharing the results of a recent healthcare survey and diving into the critical need to preserve Medicare coverage for seniors. The survey just opened, and we encourage you to add your unique perspective on the problem by answering a few questions here.
Interested in this important discussion? You can find the event details by clicking here. Go ahead and mark yourself as “going” if you plan to tune in.
We look forward to having you join us!
Oped by Mark Gibbons - President /CEO RetireSafe - Boston Herald - November 16, 2021
To help pay for the massive spending bill, congressional Democrats are planning an enormous change to Medicare. The changes will curtail access to today’s advanced medicines and stifle the development of tomorrow’s new treatments and cures.
The bill seeks to remove the Medicare drug benefit’s “non-interference” clause, which bars federal health officials from meddling in the prescription drug market. Democrats are marketing this plan as “negotiations” — because few would take issue with a good-faith back-and-forth. However, the bill explicitly plans to impose price controls.
As it currently stands, the spending package would cap the prices on branded medicines and impose a financial penalty if a drug rises in price at a pace faster than inflation.
This would completely upend Medicare.
By design, Medicare’s drug benefit was set up to be administered by private insurers. This model forces insurers to compete for seniors’ business by offering a wide variety of drug plans. Additionally, it forces drug companies to negotiate with those insurers, as they all want their medicines included on insurers’ formularies.
The government subsidizes the drug plans and requires insurers to cover many critical medicines, but otherwise, it stays out on the sidelines. This “non-interference” has turned into a critical safeguard for seniors, as it protects them from the one-size-fits-all formulary that patients face in other government-run health care programs.
Consider the Veterans Affairs drug benefit. Of the 200 most popular branded drugs in Medicare, the VA covered only 52% of them. Medicare’s drug plans, though, covered 74% of them. Government-run systems abroad are even more restrictive. American patients gained immediate access to 90% of the medicines released between 2011 and 2017. British patients could access only 60% of those drugs — and Canadians could only access 44% of them.
Setting drug prices arbitrarily would also deter companies from investing in research. It costs almost $3 billion, on average, to develop a new treatment. That cost is so high because every success story must pay for the medicines that never make it out of the lab or fail in clinical trials.
If the government starts capping prices — and thus, eliminates any potential for a return — investors’ risk calculus will change. Firms will scale back research. Funding for early-stage biotechs will effectively evaporate. The number of drugs created by those small firms will plummet 90%, according to Vital Transformation, a consulting firm.
That would turn out disastrously for America’s seniors. Nearly 6 million American seniors have Alzheimer’s today, and more than two-thirds of U.S. cancer deaths are among seniors. While we don’t have cures for these diseases today, in 10 or 20 years, we might — if our leaders don’t get in scientists’ way.
I served in the Army for 10 years, both enlisted and as an officer, and was a commander in Desert Shield and Desert Storm. I know firsthand the sacrifices our veterans make, as well as the shortcomings of the VA. Additionally, as an advocate for both veterans and seniors, I cannot stand by as Congress attempts to restrict our care and curb innovation.
Several experts echo this concern.
Tomas Philipson, who chaired President Trump’s Council of Economic Advisers, has forecast that an earlier version of this bill would prevent the development of at least 167 drugs over the next two decades, and as many as 342.
Meanwhile, the director of health policy research at the Harvard Kennedy School of Government recently predicted that a similar plan could block scientists from creating “a transformational drug for Alzheimer’s.”
What’s particularly galling is the reason Democrats are proposing these misguided reforms. The changes have little, if anything, to do with lowering patients’ out-of-pocket prices. Rather, it’s a money grab to “pay-for” the spending bill.
In effect, Democrats seem willing to sacrifice seniors’ health to pay for a spending package drafted by the far-left wing of the party. That’s unacceptable.
Hello America's Seniors,
As you age, there is greater chance of receiving a serious medical diagnosis. This can sometimes be cancer. Thanks to an educational grant from Bristol-Myers Squibb, RetireSafe is launching a webinar series partnered with the National Grange that guides you and your family through that diagnosis. The series is split into six sessions. While we hope you and your families never have to experience this life altering diagnoses, we hope this information can make the process easier for those who may face serious medical diagnoses. On July 12th the series will be posted here on our website. Check it out!